Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis

Toxicology and Applied Pharmacology

Volumn 252, Issue 2, 2011, Pages 165-175

  Shaker, Mohamed E ^a   Zalata, Khaled R ^b   Mehal, Wajahat Z ^c   Shiha, Gamal E ^b   Ibrahim, Tarek M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbon tetrachloride; Hepatic fibrosis; Imatinib; Nilotinib; Silymarin

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; COLLAGEN; HYDROXYPROLINE; IMATINIB; NILOTINIB; NITRATE; NITRITE; SILYMARIN;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; HISTOPATHOLOGY; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG FIBROSIS; LUNG INJURY; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; CARBON TETRACHLORIDE POISONING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; LIVER CIRRHOSIS; MALE; OXIDATIVE STRESS; PIPERAZINES; PYRIMIDINES; RATS; RATS, WISTAR; SILYMARIN; TREATMENT OUTCOME;

RATTUS; RATTUS NORVEGICUS;

EID: 79953705628     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.02.004     Document Type: Article

References (53)

1. Abdalla A.F., Zalata K.R., Ismail A.F., Shiha G., Attiya M., Abo-Alyazeed A. Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods. Fibrogenesis Tissue Repair 2009, 2:2.
2. Akhmetshina A., Dees C., Pileckyte M., Maurer B., Axmann R., Jungel A., Zwerina J., Gay S., Schett G., Distler O., Distler J.H. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008, 22:2214-2222.
3. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., Izumi K., Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 2005, 171:1279-1285.
4. Beyer R.E. A rapid biuret assay for protein of whole fatty tissues. Anal. Biochem. 1983, 129:483-485.
5. Boll M., Weber L.W., Becker E., Stampfl A. Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by reactive carbon tetrachloride metabolites. Z. Naturforsch. C 2001, 56:649-659.
6. Cao C., Leng Y., Huang W., Liu X., Kufe D. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J. Biol. Chem. 2003, 278:39609-39614.
7. Chandran S., Petersen J., Jacobs C., Fiorentino D., Doeden K., Lafayette R.A. Imatinib in the treatment of nephrogenic systemic fibrosis. Am. J. Kidney Dis. 2009, 53:129-132.
8. Cohen M.H., Williams G., Johnson J.R., Duan J., Gobburu J., Rahman A., Benson K., Leighton J., Kim S.K., Wood R., Rothmann M., Chen G., U K.M., Staten A.M., Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 2002, 8:935-942.
9. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., Leof E.B. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114:1308-1316.
10. D'Aura Swanson C., Paniagua R.T., Lindstrom T.M., Robinson W.H. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:317-324.
11. Day E., Waters B., Spiegel K., Alnadaf T., Manley P.W., Buchdunger E., Walker C., Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur. J. Pharmacol. 2008, 599:44-53.
12. Deremer D.L., Ustun C., Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther. 2008, 30:1956-1975.
13. Distler J.H., Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 2008, 47(Suppl 5):v10-v11.
14. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., Michel B.A., Hauser T., Schett G., Gay S., Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007, 56:311-322.
15. Edwards M.J., Keller B.J., Kauffman F.C., Thurman R.G. The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol. Appl. Pharmacol. 1993, 119:275-279.
16. El Jamali A., Valente A.J., Lechleiter J.D., Gamez M.J., Pearson D.W., Nauseef W.M., Clark R.A. Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl. Free Radic. Biol. Med. 2008, 44:868-881.
17. Friedman S.L. Hepatic fibrosis-overview. Toxicology 2008, 254:120-129.
18. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
19. Gabele E., Brenner D.A., Rippe R.A. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front. Biosci. 2003, 8:d69-d77.
20. Gascon-Barre M., Huet P.M., Belgiorno J., Plourde V., Coulombe P.A. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J. Histochem. Cytochem. 1989, 37:377-381.
21. Gerard-Monnier D., Erdelmeier I., Regnard K., Moze-Henry N., Yadan J.C., Chaudiere J. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem. Res. Toxicol. 1998, 11:1176-1183.
22. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., Jones P.L., Maitland M.L., Michelakis E.D., Morrell N.W., Newman J.H., Rabinovitch M., Schermuly R., Stenmark K.R., Voelkel N.F., Yuan J.X., Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 2009, 54:S10-S19.
23. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R.N., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995, 22:696-699.
24. Johnson J.R., Bross P., Cohen M., Rothmann M., Chen G., Zajicek A., Gobburu J., Rahman A., Staten A., Pazdur R. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res. 2003, 9:1972-1979.
25. Kong J.H., Yoo S.H., Lee K.E., Nam S.H., Kwon J.M., Lee S.M., Chang H.J., Choi M.Y., Cho M.S., Mun Y.C., Nam E., Lee S.N., Seong C.M. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007, 118:205-208.
26. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
27. Kumar S., Bharti A., Mishra N.C., Raina D., Kharbanda S., Saxena S., Kufe D. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J. Biol. Chem. 2001, 276:17281-17285.
28. Kumar S., Mishra N., Raina D., Saxena S., Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol. Pharmacol. 2003, 63:276-282.
29. Laleman W., Vander Elst I., Zeegers M., Servaes R., Libbrecht L., Roskams T., Fevery J., Nevens F. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur. J. Clin. Invest. 2006, 36:242-249.
30. Lee H.S., Shun C.T., Chiou L.L., Chen C.H., Huang G.T., Sheu J.C. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J. Gastroenterol. Hepatol. 2005, 20:1109-1114.
31. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782-1788.
32. Manley P.W., Stiefl N., Cowan-Jacob S.W., Kaufman S., Mestan J., Wartmann M., Wiesmann M., Woodman R., Gallagher N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem. 2010, 18:6977-6986.
33. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 1974, 47:469-474.
34. Mindikoglu A.L., Regev A., Bejarano P.A., Martinez E.J., Jeffers L.J., Schiff E.R. Imatinib mesylate (gleevec) hepatotoxicity. Dig. Dis. Sci. 2007, 52:598-601.
35. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5:62-71.
36. 4). J. Toxicol. Pathol. 2004, 17:219-222.
37. Moron M.S., Depierre J.W., Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta 1979, 582:67-78.
38. Natarajan S.K., Thomas S., Ramamoorthy P., Basivireddy J., Pulimood A.B., Ramachandran A., Balasubramanian K.A. Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. J. Gastroenterol. Hepatol. 2006, 21:947-957.
39. Neef M., Ledermann M., Saegesser H., Schneider V., Widmer N., Decosterd L.A., Rochat B., Reichen J. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J. Hepatol. 2006, 44:167-175.
40. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22:935-942.
41. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
42. Ruch R.J., Klaunig J.E., Schultz N.E., Askari A.B., Lacher D.A., Pereira M.A., Goldblatt P.J. Mechanisms of chloroform and carbon tetrachloride toxicity in primary cultured mouse hepatocytes. Environ. Health Perspect. 1986, 69:301-305.
43. Saad S.Y., Alkharfy K.M., Arafah M.M. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J. Pharm. Pharmacol. 2006, 58:567-573.
44. Schierwagen C., Bylund-Fellenius A.C., Lundberg C. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Meth. 1990, 23:179-186.
45. Shaker M.E., Houssen M.E., Abo-Hashem E.M., Ibrahim T.M. Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress. J. Physiol. Biochem. 2009, 65:225-233.
46. Shaker M.E., Salem H.A., Shiha G.E., Ibrahim T.M. Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam. Clin. Pharmacol. 2011, 25:248-257.
47. Sun X., Majumder P., Shioya H., Wu F., Kumar S., Weichselbaum R., Kharbanda S., Kufe D. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J. Biol. Chem. 2000, 275:17237-17240.
48. Vittal R., Zhang H., Han M.K., Moore B.B., Horowitz J.C., Thannickal V.J. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J. Pharmacol. Exp. Ther. 2007, 321:35-44.
49. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005, 19:1-11.
50. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003, 33:105-136.
51. Wolf A.M., Wolf D., Rumpold H., Ludwiczek S., Enrich B., Gastl G., Weiss G., Tilg H. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl. Acad. Sci. USA 2005, 102:13622-13627.
52. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G907-G913.
53. Yoshiji H., Kuriyama S., Noguchi R., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Yamazaki M., Asada K., Akahane T., Tsujimoto T., Uemura M., Fukui H. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int. J. Mol. Med. 2006, 17:899-904.